Chatham Capital Group, Inc. Eli Lilly & CO Transaction History

Chatham Capital Group, Inc.

$601 Million
Q3 2024

A detailed history of Chatham Capital Group, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Chatham Capital Group, Inc. holds 9,300 shares of LLY stock, worth $7.4 Million. This represents 1.37% of its overall portfolio holdings.

Number of Shares

9,300

Previous 9,064 2.6%

Holding current value

$7.4 Million

Previous $8.21 Million 0.4%

% of portfolio

1.37%

Previous 1.45%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$772.14 - $960.02 $182,225 - $226,564	236 Added 2.6%	9,300 $8.24 Million
Q2 2024 Jul 15, 2024	BUY	$724.87 - $909.04 $191,365 - $239,986	264 Added 3.0%	9,064 $8.21 Million
Q1 2024 Apr 17, 2024	BUY	$592.2 - $792.28 $445,334 - $595,794	752 Added 9.34%	8,800 $6.85 Million
Q4 2023 Jan 19, 2024	BUY	$525.19 - $619.13 $38,864 - $45,815	74 Added 0.93%	8,048 $4.69 Million
Q3 2023 Oct 25, 2023	BUY	$434.7 - $599.3 $184,312 - $254,103	424 Added 5.62%	7,974 $4.28 Million
Q2 2023 Jul 13, 2023	SELL	$350.74 - $468.98 $173,616 - $232,145	-495 Reduced 6.15%	7,550 $3.54 Million
Q1 2023 Apr 21, 2023	BUY	$310.63 - $364.82 $361,883 - $425,015	1,165 Added 16.93%	8,045 $2.76 Million
Q4 2022 Jan 31, 2023	BUY	$321.55 - $374.67 $179,424 - $209,065	558 Added 8.83%	6,880 $2.52 Million
Q3 2022 Oct 28, 2022	BUY	$296.48 - $337.87 $82,124 - $93,589	277 Added 4.58%	6,322 $2.04 Million
Q2 2022 Aug 02, 2022	BUY	$278.73 - $327.27 $35,677 - $41,890	128 Added 2.16%	6,045 $1.96 Million
Q1 2022 Apr 21, 2022	BUY	$234.69 - $291.66 $312,137 - $387,907	1,330 Added 28.99%	5,917 $1.69 Million
Q4 2021 Feb 02, 2022	BUY	$224.85 - $279.04 $29,230 - $36,275	130 Added 2.92%	4,587 $1.27 Million
Q3 2021 Oct 13, 2021	BUY	$221.6 - $272.71 $48,087 - $59,178	217 Added 5.12%	4,457 $1.03 Million
Q1 2021 Apr 29, 2021	SELL	$164.32 - $212.72 $32,864 - $42,544	-200 Reduced 4.5%	4,240 $792,000
Q4 2020 Jan 27, 2021	BUY	$130.46 - $172.63 $13,046 - $17,263	100 Added 2.3%	4,440 $750,000
Q3 2020 Oct 22, 2020	SELL	$146.22 - $169.13 $29,244 - $33,826	-200 Reduced 4.41%	4,340 $642,000
Q2 2020 Jul 20, 2020	BUY	$136.42 - $164.18 $6,820 - $8,209	50 Added 1.11%	4,540 $745,000
Q1 2019 May 09, 2019	SELL	$111.31 - $131.02 $7,235 - $8,516	-65 Reduced 1.43%	4,490 $583,000
Q4 2018 Feb 06, 2019	SELL	$105.9 - $118.64 $3,706 - $4,152	-35 Reduced 0.76%	4,555 $527,000
Q2 2018 Jul 30, 2018	BUY	$75.7 - $86.88 $11,355 - $13,032	150 Added 3.38%	4,590 $392,000
Q1 2018 May 09, 2018	SELL	$74.21 - $87.6 $7,420 - $8,760	-100 Reduced 2.2%	4,440 $344,000
Q2 2017 Aug 09, 2017	BUY	N/A	4,540	4,540 $374,000

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chatham Capital Group, Inc. with notifications on news.

Account

Chatham Capital Group, Inc. Eli Lilly & CO Transaction History